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Endometriosis is an estrogen-dependent disorder where endometrial tissue forms lesions outside the
uterus. Endometriosis affects an estimated 10% of women in the reproductive-age group, rising to
30% to 50% in patients with infertility and/or pain, with significant impact on their physical, mental,
and social well-being. There is no known cure, and most current medical treatments are not suitable long
term due to their side-effect profiles. Endometriosis has an estimated annual cost in the United States of
$18.8 to $22 billion (2002 figures). Although endometriosis was first described more than 100 years
ago, current knowledge of its pathogenesis, spontaneous evolution, and the pathophysiology of the related
infertility and pelvic pain, remain unclear. A consensus workshop was convened following the 10th
World Congress on Endometriosis to establish recommendations for priorities in endometriosis research.
One major issue identified as impacting on the capacity to undertake endometriosis research is the need for
multidisciplinary expertise. A total of 25 recommendations for research have been developed, grouped
under 5 subheadings: (1) diagnosis, (2) classification and prognosis, (3) treatment and outcome, (4) epi-
demiology, and (5) pathophysiology. Endometriosis research is underfunded relative to other diseases
with high health care burdens. This may be due to the practical difficulties of developing competitive
research proposals on a complex and poorly understood disease, which affects only women. By producing
this consensus international research priorities statement it is the hope of the workshop participants that
researchers will be encouraged to develop new interdisciplinary research proposals that will attract increased
funding support for work on endometriosis.
KEY WORDS: Endometriosis, research directions, international workshop, consensus report.
INTRODUCTION
Immediately following the 10th World Congress on
Endometriosis held in Melbourne in March 2008, a
World Endometriosis Society (WES) and World Endo-
metriosis Research Foundation (WERF)–endorsed
workshop of interested persons was convened to develop
a global consensus statement of research directions and
priorities in endometriosis. Although by no means
proscriptive, it is hoped that these recommendations will
act as both a guide and a stimulus to the international
research community, as well as the many funding agencies
that may provide support for endometriosis research.
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At the workshop a number of speakers were invited
to introduce different endometriosis-related topics, with
each presentation being followed by open discussion
involving all participants. To provide a framework for the
many recommendations developed during the workshop,
a series of headings has been used that follows the progress
of the disease from diagnosis through classification and
prognosis to treatment and outcome. Impacting on each
of these groupings are the major areas of disease epide-
miology and pathophysiology. A representation of this
framework is shown in Figure 1.
BACKGROUND
Endometriosis is an estrogen-dependent disorder, defined
as the presence of endometrial tissue outside of the uterus
in lesions of varying sizes and appearance containing
endometrial glands and stroma. It may be asymptomatic
or associated with symptoms of pain and/or infertility.
It is found on the peritoneum and ovaries, in the recto-
vaginal septum, and in other sites within and outside the
pelvis. Endometriosis affects an estimated 1 in 10 women
in the reproductive-age group.1 This prevalence increases
up to 30% in women with infertility2 and to 50% in
infertile women with a normal cycle whose partner has
normal sperm.3 Although it is difficult to generate accu-
rate figures for costs associated with endometriosis, 2
recent studies have estimated an annual cost using 2002
figures for endometriosis in the United States at $18.8 and
$22 billion when direct treatment costs and indirect costs
such as lost work productivity are combined.4,5 Although
the existence of endometriosis has been known for more
than 100 years, our current knowledge of its pathogen-
esis, the spontaneous evolution of the disease, and the
pathophysiology of the related infertility and pelvic pain,
remain unclear. One of the major issues identified as
impacting on the capacity to undertake endometriosis
research is the need for multidisciplinary expertise, in
conjunction with sufficient funding to allow meaningful
projects to be undertaken.
Recommendation
There is a need for a multidisciplinary approach to research
in all aspects of endometriosis, to include reproductive
medicine physicians, reproductive medicine surgeons, biol-
ogists, pathologists, oncologists, epidemiologists, geneticists,
immunologists, toxicologists, pain specialists, infectious dis-
ease specialists, biostatisticians, bioinformaticians, and others
to enable effective, accurate, and timely diagnosis, determi-
nation of those at risk, and prevention and treatment of
endometriosis, and associated disorders.
DIAGNOSIS OF ENDOMETRIOSIS
Of the several factors that contribute to our lack of under-
standing of endometriosis, perhaps the most significant is
the 8 to 11 years delay that typically precedes an accurate
diagnosis of the disease.6 The problem of diagnosing
endometriosis is further compounded by the fact that
many patients suffer from comorbidities, such as adeno-
myosis, irritable bowel syndrome, and interstitial cystitis,
which can all contribute to the symptomatology. In con-
trast to diagnosis of endometriosis at surgery, noninvasive
diagnostic methods that can be used to effectively and
economically screen for endometriosis are urgently
required. Identification of biomarkers for early noninva-
sive diagnosis and for following the progression of endo-
metriosis was identified as a priority for investigation as
well as early clinical application. The greatest need is for
noninvasive detection of minimal-mild endometriosis,
given that moderate-severe forms of the disease are more
likely to be identified by clinical examination and/or
imaging.7 Because of the likely variable etiology of the
disease, ‘‘fingerprints’’ rather than individual molecules
will probably be required. It is also possible that different
subsets of biomarkers may be required for different stages
or clinical classifications of endometriosis.
Recommendation
Biomarkers are required that will provide an accurate,
noninvasive method to diagnose endometriosis.
Epidemiology 
Diagnosis 
Treatment
& outcome  
Classification
& prognosis  
Patho
physiology 
Figure 1. Diagram of schema used to group endometriosis research
recommendations.
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Different techniques for diagnostic and preoperative
imaging of endometriosis are being explored, including
ultrasound, computer tomography (CT), and magnetic
resonance imaging (MRI). From a clinical point of view,
the ideal is for a test with high sensitivity that does not
miss any individuals with endometriosis or other pelvic
conditions that might benefit from diagnostic or operative
laparoscopy.7 Although the resolution of imaging
techniques continues to improve, their current diagnostic
accuracy remains significantly inferior to direct laparo-
scopic visualization. Other issues associated with imaging
of endometriosis are the training required to achieve
acceptable sensitivity and specificity rates, and the cost
of these procedures if used as a screening tool.
Recommendation
Advances in imaging techniques should be monitored for
application to diagnosis of endometriosis.
There is significant cost and expertise associated with
collecting adequate numbers of well-characterized endo-
metriotic lesions, peripheral blood samples, and other
tissue specimens required for endometriosis research.
Such samples have the greatest value when collected
using systematic protocols and accompanied by detailed
clinical classification of the patients.
Recommendation
That networks and/or biobanks and databases replete
with patient clinical data are established to increase sample
availability and improve study power for endometriosis
research, including assessment and validation of biomar-
kers. Standard operating procedures should be established
for tissue acquisition, processing, storage, and distribution.
These activities should take account of existing databases
and resources regarding patients with endometriosis.
Recommendation
That the effect of surgical sampling methods (laser, scissor,
unipolar coagulation, etc) on the quality of tissues for research
and influences on biomarker expression be analyzed: includ-
ing the impact of anesthesia/analgesia at the time of surgery.
CLASSIFICATION AND PROGNOSIS
During the workshop, detailed discussion was held on the
need for and difficulties associated with standardization of
disease classification. The revised American Fertility
Society (rAFS) classification of endometriosis8 and the
revised American Society for Reproductive Medicine
classification of endometriosis 2006 are the current gold
standards.9 However, these are restricted to a limited
number of criteria and are not particularly valuable for
predicting pain or fertility outcomes. Although there is
poor correlation between stage of disease and pain scores
using the above classification systems, there is good corre-
lation with type of lesion and pain.10-12 In the broadest
sense, classification may be related to risk of endometrio-
sis, the etiology of the disorder (including genetic and
environmental factors), disorders associated with endo-
metriosis, targeting therapies, and designing inclusion/
exclusion criteria for clinical trials to evaluate diagnostics
and therapeutics. Interestingly, the transcriptomes of
eutopic endometrium and ectopic endometrial lesions
suggest that ovarian endometriosis and peritoneal disease
are different disorders13 and that, in contrast to the
presence of ovarian and peritoneal disease, recto-vaginal
disease does not affect gene expression in eutopic endo-
metrium.14 These observations may give insight into
developing a more comprehensive and meaningful
classification system that has clinical prognostic value in
determining issues like why some women develop deep
infiltrating endometriosis while in others the disease
remains limited. The choice of controls is crucial in
studies investigating environmental risk-factors for
endometriosis, but is also an important issue in genetic
case-control studies. For both types of studies, use of gen-
eral population controls carry the problem that they
cannot be screened for absence of disease, resulting in a
reduction of power of a study. In genetic studies, the addi-
tional main concern is for controls to be selected from the
same ethnic background as cases, to avoid spurious findings
related to population differences (population stratification).
Recommendation
Reporting standards with detailed clinical, symptom, and
diagnosis information should be developed to allow better
comparison between studies and to improve our ability to
combine the results from different centres to increase the
power of individual studies.
Recommendation
A standardized classification of endometriosis should be
developed based on lesion number, size, appearance, loca-
tion, pain symptoms, presence or absence of infertility,
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pain and infertility, age of onset, family history/genetics,
associated disorders, and yet to be developed biomarkers.
TREATMENT AND OUTCOME
Current treatment options for women with endometriosis-
associated pain and/or infertility include surgery, medical
treatment, alternative therapies, and assisted reproduc-
tion. Professional guidelines for the clinical management
of endometriosis, like the ESHRE Guidelines15 and the
Practice Guidelines of the American Society for
Reproductive Medicine,16 exist and it is important to
ensure that these guidelines are continually reviewed and
updated to reflect the latest clinical and scientific findings,
and that they are adopted by health care professionals
worldwide. There is a clear need for further research
aimed at improving endometriosis treatment outcomes.
Examples include, but are not limited to, (1) whether
effective medical adjuvant therapies exist to prevent or
limit the recurrence of lesions and symptoms following
surgery, (2) whether laparoscopic ablation or excision of
endometriosis is more effective in women with pain (3)
whether all, or some categories of endometriotic lesions
need to be treated prior to infertility treatment by IVF,
(4) whether pain-free women with endometriosis who
need in vitro fertilization (IVF) for other reasons actually
benefit from being disease-free, (5) whether the introduc-
tion of advanced operative laparoscopy techniques have
resulted in an increase in adverse outcomes relating to
long-term bladder, bowel, or ovarian dysfunction, and
whether such techniques are superior to more conservative
surgery in preventing long-term recurrence of endometriosis.
Recommendation
There is a need for more well designed, adequately
powered, multicenter randomized controlled trials and
long-term follow-up studies comparing different endo-
metriosis treatment options against defined outcome
measures.
Development of nonhormonal medical treatments to
prevent or treat endometriosis and associated symptoms is
a priority.17 Such treatments should reduce pain and sub-
fertility without suppression of ovulation, and ideally
provide the option of a normal and safe pregnancy during
treatment. New drug targets are currently being devel-
oped in the area of cancer and chronic inflammatory dis-
eases that may be relevant for treatment of endometriosis.
Potential mechanisms of action that could be relevant to
the treatment of endometriosis include inhibition of:
inflammation (tumor necrosis factor alpha [TNF-a] inhi-
bitors, COX-2 inhibitors), fibrosis, pain, angiogenesis,
and matrix metalloproteinases. Further work is also
required to assess the value of selective estrogen and
progesterone receptor modulators.
Recommendation
Novel medical treatments for endometriosis should be
investigated.
It was also noted that surgical and clinical trials offer
an excellent opportunity to obtain well characterized
tissue samples for collaborative studies on the pathophy-
siology of endometriosis.
Recommendation
Efforts should be made to maximize the amount of data
that are generated from clinical trials through add-on
studies and collaboration with other relevant disciplines.
EPIDEMIOLOGY
Endometriosis is a complex disease influenced by both
environmental and genetic factors.18-20 Current evidence
from a range of studies supports a genetic contribution to
endometriosis risk.20 The genetic contribution was ques-
tioned recently21 because of problems with the design of
many studies, relating to small sample sizes, ascertainment
bias, increased opportunity for diagnosis among family
members of cases compared with controls, and familial
aggregation of confounding risk factors such as early
age at menarche and environmental exposures.21 It is
certainly true that studies of endometriosis, in particular
those involving candidate genes, have suffered serious
methodological problems.22 However, more recent,
larger studies in Australian twins,18 in the Icelandic
population,23 in rhesus macaques,24 as well as the signifi-
cant linkage to chromosome 10 found in a large colla-
borative study of 1176 families,25 address many of these
concerns and together provide strong evidence for a
genetic contribution to the disease.
Although the balance of evidence supports a genetic
contribution to the risk of developing endometriosis, the
concerns about study design21 highlight general problems
for both epidemiological and genetic studies in endome-
triosis.22 Endometriosis can only be diagnosed following
invasive procedures such as laparoscopy, and there is often
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a long gap between first symptoms and disease diagnosis.6
The lack of a noninvasive test means there are no good
estimates of disease prevalence in the general population
and there are difficulties in defining both case and control
groups in systematic studies. As discussed by Di and
Guo21 and in other recent reviews,26,27 the interpretation
of many published genetic and epidemiological studies is
problematic. There are a number of issues that must be
addressed in future studies if we are to make substantive
progress in understanding this disease.
Genome-wide association methods offer a powerful
approach for making progress in the discovery of genes
influencing risk of endometriosis. Sample size should
have sufficient power to detect expected effects (genoty-
pic odds ratios of 1.2-1.5) for a complex disease like
endometriosis. For genome-wide association studies, this
figure should be at least 2000 cases and 2000 controls to
detect common genetic variants; when stratified analyses
are anticipated (eg, on disease severity) this number needs
to be increased accordingly. Minimum sample sizes for
environmental or candidate gene studies should be in the
range of 1000 cases and 1000 controls.28 Future studies of
gene-environment interaction are likely to require sample
sizes in the range of 5000-10 000 cases and an equal
number of controls.
Recommendation
Collaborations be established between research groups
with sufficient participant numbers and appropriate stan-
dardization of sample and information collection to iden-
tify genetic and environmental influences on
endometriosis.
Recommendation
Additional samples of phenotypically well-characterized
endometriosis cases and controls should be collected from
different ethnic groups for replication and evaluation of
positive genetic associations.
Data from animal models and from women suggest
that environmental contaminants, specifically endocrine
disrupting chemicals, may contribute to the pathogenesis
of endometriosis. Timing of exposure appears to be
important, as in utero exposure to the xenoestrogen
diethylstilbesterol (DES) increases a woman’s risk of
developing endometriosis as an adult by 80% (RR ¼
1.8, CI ¼ 1.2-2.8).29 In addition, mice exposed in utero
to the dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), on gestational day 8 have larger transplanted
endometriotic lesions when combined with an adult
exposure, compared to an adult exposure alone.30 Thus,
it has been hypothesized that during embryogenesis,
endocrine disrupting chemical (EDC) exposure has an
organizational effect that increases susceptibility to endo-
metriosis, but subsequent adult hormone/immune/EDC
irregularities are required for disease onset.31
There is overwhelming evidence from nonhuman
primate and rodent studies suggesting that endometriosis
can be promoted by adult exposures to organochlorines
(OCLs), a class of chemicals that includes the dioxin,
TCDD, the pesticides methoxychlor and DDT, and
polychlorinated biphenyls with dioxin-like effects.31
However, data in humans linking OCL exposure and
endometriosis are equivocal, because of inherent weak-
nesses of observational epidemiology studies, limited
sample sizes, and potential confounding variables.31
Dysfunction of the immune system influenced by
endocrine disrupting chemicals (eg, TCDD) is also con-
sidered relevant because although high levels of activated
macrophages and inflammatory cytokines are present in
the peritoneal environment, in women with peritoneal
endometriosis the immune system fails to clear the
lesions.32 Thus, the progression of endometriosis is
dependent on both hormonal and immune environ-
ments, but the exact etiology of endometriosis onset is
unclear.
Recommendation
Further research on an environmental etiology of endo-
metriosis is warranted, with windows of susceptibility (life
stages) being an important criteria in the collection of
information. Although measurements of individual and
mixtures of endocrine disrupting chemicals (and other
environmental contaminants) can be challenging, timing
of exposure, dose, and duration are important to deter-
mine, if known, and should be included in databases,
where possible.
PATHOPHYSIOLOGY
A wide range of disciplines and experimental approaches
relevant to the study of endometriosis can be listed under
the general heading of pathophysiology. These include
physiology, pathology, immunology, endocrinology,
inflammation, and pain, each of which can encompass
approaches such as genomics, proteomics, and animal and
in vitro models. The workshop did not attempt to
Priorities for Endometriosis Research Reproductive Sciences Vol. 16, No. 4, April 2009 339
develop a comprehensive set of recommendations topic
by topic for each of these combinations, but rather to
identify major themes and areas of importance.
The pathology of endometriosis lesions can vary
widely.33 This is often not recognized or acknowledged
by investigators, and raises critical questions about both
the heterogeneity of endometriosis as a disease, and the
normal life cycle of different endometriotic lesions. There
is little understanding of whether the range of symptoms
suffered by women with endometriosis can be linked to
the different types of lesions. Substantial work is required
to link lesion pathology to symptoms, the results of which
will play a critical role in determining whether stratifica-
tion of endometriosis patients into subgroups is required
for epidemiological, diagnostic, prognostic, and treatment
studies. Pathology studies should have broad scope and
include histology, immunohistochemistry, molecular, and
proteomics approaches.
Recommendation
Heterogeneity of endometriosis lesions should be investi-
gated using the full range of pathological and analytical
approaches to ascertain whether an association exists between
different lesion types and any given symptomatology.
Numerous studies have reported differences between
eutopic endometrium from women with endometriosis
compared to those that do not have the disease.34 Studies
in baboons have confirmed that major changes in eutopic
endometrial gene expression occur following the
induction of endometriosis,35 although the biological
mechanisms driving these changes are yet to be eluci-
dated. A crucial question is whether surgical treatment
of these induced endometriotic lesions reverses the
observed eutopic endometrial changes. Whether signifi-
cant differences exist in eutopic endometrium between
women destined to develop endometriosis and those that
will not, prior to the spontaneous development of the dis-
ease, is also unknown.
Recommendation
A better understanding of the role of eutopic endome-
trium in the establishment and continuation of endome-
triosis is required.
Eutopic endometrium is generally considered the
source of at least the majority of the cells that form endo-
metriotic lesions following reflux of menstrual debris into
the peritoneal cavity. In addition to tissue fragments and
cells, menstrual effluent contains many leukocytes and
soluble mediators released during menstruation, including
cytokines and proteases such as matrix metalloproteinases.
The components of this effluent and of the peritoneal
fluid are likely to contribute to the fate of the endometrial
tissue that reaches the peritoneum. However, the exact
prevalence and quantity of endometrial tissue present in
peritoneal fluid at the time of menstruation is not known.
Furthermore, the capacity of the peritoneal fluid and its
cellular components to ‘‘neutralize’’ or degrade active
mediators, and of the peritoneal leukocytes to remove
cellular debris, or to promote endometrial adhesion or
peritoneal metaplasia needs more research, since these
factors may be important in determining whether or not
endometriosis can be established.
Recommendation
Research should be performed on menstrual tissue,
including material obtained from the peritoneal cavity
by laparoscopy performed at the time of menstruation.
Differences in retrogradely shed menstrual material
between women with and without endometriosis should
be defined, including but not limited to soluble media-
tors, endometrial cells, and leucocytes.
The hypothesis that endometriosis lesions may be
established by single or small groups of menstrual endo-
metrial cells is consistent with the presence of endometrial
stem or progenitor cells. Recent work by several different
groups36-39 has confirmed the existence of putative endo-
metrial epithelial and mesenchymal stem/progenitor
cells. Whether these cells play a role in the establishment
of endometriotic lesions remains to be discovered. How-
ever the recent identification of endometrial mesenchy-
mal stem-like cell markers40 should facilitate examining
their role in the development of endometriotic lesions.
Bone marrow stem cells may also contribute to the
progression of endometriotic lesions by incorporating
into developing lesions and transdifferentiating into
endometriotic cells.41
Recommendation
Functional properties of endometrial cells expressing stem
cell markers should be investigated and menstrual endo-
metrium examined for endometrial stem/progenitor cells
using any newly identified markers. The role of bone
marrow–derived cells in endometriotic lesion development
should be further investigated. Developmental signaling
pathways should also be examined in endometrial stem/
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progenitor cells and in models examining the metaplasia
and fetal stem cell theories of endometriosis.
Many immune mediators (both leukocyte subsets and
cytokines) have been identified as being different in the
eutopic endometrium and peritoneal fluid between
women without and those with endometriosis as well as
within ectopic lesions. Leukocyte numbers, subsets, and
particularly their activation states vary normally in the
endometrium in a cycle-dependent manner, but it is not
clear how closely these relate to those within the perito-
neal cavity or in the lesions, or whether inflammatory
responses are altered in women with endometriosis.
There is an inflammatory cascade of events (Figure 2)
where some of the mediators (such as prostaglandins) can
also cause pain. Disturbance of this cascade toward a more
inflammatory phenotype can occur at any point in the
cascade. Furthermore, studies on individual cells or
mediators are likely to be of limited value given the con-
siderable overlap among their actions. Application of
systems biology is more likely to reap rewards in terms
of understanding how disturbance to this system relates
to establishment of disease and its severity and to the
related pain caused by the inflammation. Given that inflam-
mation and specific immune responses differ between
animal models (particularly various immune-deficient
mice) these could be exploited.
Recommendation
The inflammatory response is an important avenue for
further research and should focus wherever possible on
a systems biology approach rather than individual compo-
nents of the inflammatory pathway.
Alleviation of pain due to endometriosis is a high
priority. Despite this, very little research is being
undertaken in this area, possibly because of difficulties
in establishing appropriate multi-disciplinary collaborative
teams. The recent identification of increased nerve fiber
density in endometrium from women with endometriosis42
may be highly significant in this regard.
Recommendation
That understanding the origins of the pain associated with
endometriosis is a priority for endometriosis research:
such work should include specialists in the pain field.
Progestins have overall anti-inflammatory activity,
and there appears to be progesterone-resistance in endo-
metriotic lesions and eutopic endometrium of women
with endometriosis. Given that different progestins have
different glucocorticoid and androgenic activity there
may be opportunities for modifying treatments to
improve outcomes. Similarly, selective progesterone
receptor modulators (SPRMs) appear promising in treat-
ing endometriosis.
Recommendation
Clinical and basic studies should be undertaken to deter-
mine the effectiveness of different progestins and SPRMs
as agents for treating endometriosis.
The choice of models for endometriosis research is
often debated, with no single model absolutely replicating
all aspects of the human disease. One relatively popular
model uses the transplantation of human endometrial tis-
sue into immunocompromized mice, resulting in steroid
responsive xenografts with limited graft rejection.43-45
Other investigators have used allotransplantation of
uterine endometrium from syngeneic mice.46 These mod-
els are advantageous because they have limited cost and
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Figure 2. Activation of an inflammatory cascade within the
peritoneal environment/endometriotic lesion can enhance the
invasiveness of the lesion and contribute to pain.
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large experimental groups can be used. Moreover, these
animals are usually ‘‘inbred’’ and experimental results are
more reproducible than usually seen in human and non-
human primate participants. However, while rodents can
provide an excellent approach to investigate endometriosis,
there are limitations to these models. Despite increased
ethical scrutiny, nonhuman primates (in particular the
baboon and the rhesus macaque) offer several significant
advantages including reproductive anatomy, endocrinol-
ogy and physiology that is similar to humans, spontaneous
development of endometriosis which is histologically
similar to the human disease, and the ability to induce
endometriosis by autologous intrapelvic injection of
menstrual endometrium.47-49 Nonhuman primate
models can be used to study longitudinal progression of
the disease with multiple surgical procedures possible.
Additionally, the close phylogenetic relationship with
humans permits the use of human molecular probes and
antibodies and allows the testing of potentially interesting
new drugs in the prevention or treatment of endometrio-
sis.50,51 Extended nonhuman primate pedigrees also
provide an excellent opportunity to further interspecies
research into genetic etiologies, especially given the recent
advances in reporting of nonhuman primate genomes.
Ultimately, animal and in vitro models need to be
selected to most appropriately answer the scientific ques-
tions being asked. However, it is important to develop
and work with models that are appropriate and that can
subsequently be used for the screening and testing of
future potential therapeutic agents.
Recommendation
Appropriate animal and in vitro models for studying differ-
ent aspects of endometriosis pathophysiology should be
agreed upon by the endometriosis research community.
The coexistence of endometriosis and ovarian cancer
has been reported to range between 0.7% and 5.0% of
all cases with ovarian endometriosis,52-55 and 2 case-
controlled studies by Ness and colleagues have revealed
endometriosis as a risk factor for ovarian cancer.56,57 In
a study using the National Swedish Inpatient Register,
women discharged from a hospital between 1969 and
2000 with a diagnosis of endometriosis were identified
and the data linked to the National Swedish Cancer
Register to find cases that developed cancer.58 Although
the overall risk of cancer was not increased in a cohort of
64 492 women, an elevated risk was found for ovarian
cancer (standardized incidence ratio [SIR] 1.43, 95%
CI 1.19-1.71), and women with early diagnosed and
long-standing endometriosis were at even higher risk
(SIRs of 2.01 and 2.23, respectively). In addition, women
with endometriosis had higher risks of endocrine tumors
including cancer of the adrenal, thyroid, parathyroid, pitui-
tary, and insulinoma of the pancreas (SIR 1.36, 95%
CI 1.15-1.61). Increased risk was also observed for non-
Hodgkin’s lymphoma (SIR 1.24, 95% CI 1.02-1.49) and
brain tumors (SIR 1.22, 95% CI 1.04-1.41). Women
who were hospitalized for the first time with a diagnosis
coded for endometriosis between the ages of 50 and 60
had an increased risk of breast cancer (SIR 1.28, 95%
CI 1.13-1.45). Women with endometriosis-associated
ovarian carcinoma tend to have a lower stage of cancer,
different histological subtypes compared to the general
population, predominantly lower grade endometriosis
lesions, and significantly better overall survival compared
to women with serous adenocarcinoma, which is the
most common type in the general population.59 Synchro-
nous incidence of endometriosis with clear cell (41%) and
endometrioid (38%) ovarian carcinoma suggests malig-
nant transformation,60 and the recent mouse model of
over expression of k-Ras in the ovarian epithelium and
targeted deletion of PTEN with development of endo-
metriosis and endometroid ovarian cancer provide one
possible mechanism for the malignant transformation of
endometriosis to ovarian cancer.
Recommendation
More basic research is needed on mechanisms and risk
factors underlying transformation of ovarian endometrio-
sis to ovarian cancer and the mechanisms underlying
higher risk of developing breast cancer, non-Hodgkin’s
lymphoma, and brain cancer.
Recent evidence shows that in addition to eutopic
endometrium and peritoneal fluid, macroscopically nor-
mal peritoneum localized at the pelvic brim is biologically
different between women with and without endometrio-
sis.61 These data suggest that pelvic peritoneum may not
be a passive recipient of endometrial tissue, but may be
actively involved in the pathogenesis of endometriosis.
Recommendation
More research is needed to better understand the biology
and function of macroscopically normal peritoneum in
women with and without endometriosis.
The more advanced forms of endometriosis are asso-
ciated with significant fibrosis and adhesions within the
peritoneal cavity. It is not known why some women
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develop significant fibrosis and adhesions as a sequel of
endometriosis while others do not.
Recommendation
A better understanding of the mechanisms that underlie
fibrosis and adhesion formation in the peritoneal cavity
of women with endometriosis is required.
Although diet and nutrition play a major role in lifestyle
changes that many women consider when confronted with
endometriosis, there is a paucity of evidence-based litera-
ture available on this topic.62 Of the studies that have been
undertaken, no clear consensus recommendations have
emerged on what food types to eat or avoid, to reduce the
symptoms of endometriosis and/or the underlying disease.
Recommendation
Research is needed to elucidate the role/link of diet in
endometriosis.
DISCUSSION
Although investigator-driven research ideas are fundamen-
tal to scientific progress, it can also be useful for groups of
experts in a given field to develop consensus statements on
issues of importance within their area of expertise. This
document builds on earlier efforts to develop a research
priorities consensus statement for endometriosis.63
The importance of a disease is often determined by its
cost to society. From that perspective, cardiovascular
disease, cancer, and chronic diseases such as diabetes are
generally ranked highly on the scale of ‘‘priority diseases,’’
and subsequently research into these diseases is well
funded. The cost of endometriosis to women with the
disease and to society is not well known, but as stated ear-
lier has been estimated by 2 different studies at $18.8 and
$22 billion respectively in the US using 2002 data,4,5
which is substantially higher than estimated costs associ-
ated with diseases such as Crohn’s disease ($865 million)
and migraine ($13-17 billion).5 These data are largely
based on studies carried out in the United States, and the
cost of endometriosis in other countries is less well
researched. Regardless of the precise costs of endometrio-
sis to society, there seems little doubt that research into
this disease is significantly under-funded in many, if not
all, countries relative to other diseases with major health
care burdens. The reason for this underfunding is unclear,
but may reflect to some extent the practical difficulties of
developing competitive research proposals when working
on such a complex and poorly understood disease, which
only affects women. It is the hope of the workshop orga-
nizers and participants that this international consensus
document will be a useful tool in aiding researchers to
develop new interdisciplinary research proposals and
obtain increased funding support from multiple disciplines
for work on endometriosis. The workshop organizers also
recognize the strong and active endometriosis patient
advocacy groups that exist around the world, and hope that
this consensus statement will provide a valuable resource
for their efforts to increase awareness of, and funding sup-
port for research into, all aspects of endometriosis.
This research priorities consensus statement will have
a limited life, and a revised and updated set of research
priorities which builds on this document, and progress
as a result of our efforts, will be developed in conjunction
with the 11th World Congress on Endometriosis to be
held from 4 to 7 September 2011, in Montpellier, France.
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